A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Trial Profile

A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms PARAMOUNT
  • Sponsors Eli Lilly
  • Most Recent Events

    • 31 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 11 Oct 2016 Results of pooled analysis of three phase III trials (JMDB, PARAMOUNT and JMII; n=1064) were presented at the 41st European Society for Medical Oncology Congress
    • 07 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top